VIP has no approved dose for the uses discussed in the peptide community, so every figure here describes what a specific source reported rather than a prescribing guideline. The most commonly cited community regimen is intranasal, drawn from the CIRS literature; clinical aviptadil trials used their own separate protocols.[1][2]
Reviewed for accuracy · Last reviewed July 8, 2026There is no approved or validated dose for the community uses discussed here. The figures below simply describe what published sources reported, not a recommendation.
The intranasal figure most often repeated is 50 mcg per spray, up to four times daily, taken from a single small open-label CIRS study in which patients later self-titrated downward. Because that study had no control group, this should be read as a description of what was done, not evidence that it is safe or effective.
Clinical aviptadil dosing is different again: the inhaled phase 2 COVID-19 trial used a 100 mcg/mL solution given once daily, while the intravenous program used continuous infusion protocols. None of these translate into a validated dose for personal research use.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.